标记临床研究 XOMA 深 沪
已收盘 05-15 16:00:00 美东时间
41.75
-0.250
-0.60%
华盛通- 最 高41.89
- 今 开41.84
- 成交量 10.25万股
- 最 低 41.55
- 昨 收 42.00
- 总市值 5.06亿
- 52周最高 42.81
- 市盈率 静 28.67
- 换手率 0.85%
- 52周最低 22.29
- 委 比 60.68%
- 总股本 1212.94万
- 历史最高 191.40
- 量 比 0.93
- 振 幅 0.81%
- 历史最低 3.96
- 每 手 1
- 风险率 5.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅128.69%！Immunic获HC Wainwright & Co.升目标价至22美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immunic"买入"评级，目标价从5美元升至22美元；花旗：维持ServiceNow"买入"评级，目标价从154美元升至158美元
05-01 10:49
Ligand to buy XOMA Royalty for $39/share
Ligand Pharmaceuticals (LGND) has agreed to acquire XOMA Royalty (XOMA) for $39.00 per share of common stock in cash, for a total equity value of approximately $739M. The transaction has been unanimou...
04-27 19:32
Ligand Pharmaceuticals To Acquire XOMA Royalty For $39.00 Per Share In Cash, Ligand Raises FY2026 Adj. EPS Guidance To $8.50-9.50 And Expects The Transaction To Be Accretive By $1.50 Per Share To Adj. EPS In 2027
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), both biotechnology royalty aggregators, today announced that the companies have entered into a definitive
04-27 19:06
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand Pharmaceuticals to acquire XOMA Royalty for $39 per share, totaling $739 million. The deal adds over 120 assets, including 7 commercial products and nearly doubles Ligand's Phase 2 and 3 pipeline. Ligand expects the transaction to be immediately accretive to EPS, raising 2026 adjusted EPS guidance to $8.50-$9.50 and adding $1.50 per share in 2027. The acquisition is expected to close in Q3 2026, subject to regulatory approvals and stockhol...
04-27 11:00
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
XOMA Royalty Corporation (XOMA) Gets a Buy from H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on XOMA Royalt...
03-20 18:36
HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Maintains $97 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA Royalty (NASDAQ:XOMA) with a Buy and maintains $97 price target.
03-20 18:30
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty Corporation announced cash dividends for its Series A and Series B Cumulative Preferred Stock. Series A holders will receive $0.53906 per share, while Series B depositary shares will receive $0.52344 per share. Payments are scheduled for April 15, 2026, to holders of record as of April 2, 2026. XOMA Royalty specializes in acquiring future economic rights from biotech therapies, providing non-dilutive funding to sellers and potential ...
03-18 20:30
Earnings Scheduled For March 18, 2026
Companies Reporting Before The Bell • SailPoint (NASDAQ:SAIL) is estimated to r...
03-18 19:11
XOMA Q4 EPS $0.26 Beats $(0.15) Estimate, Sales $13.757M Beat $11.049M Estimate
XOMA (NASDAQ:XOMA) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $(0.15) by 267.74 percent. This is a 157.78 percent increase over losses of $(0.45) per share from the same
03-18 18:34
